688658 悦康药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-3.215-7.6133.4534.8788.472
总资产报酬率 ROA (%)-2.047-4.7982.1243.1015.712
投入资产回报率 ROIC (%)-2.575-6.0872.8014.1527.546

边际利润分析
销售毛利率 (%)55.74650.19257.80162.67164.645
营业利润率 (%)-8.390-9.5854.2075.5237.881
息税前利润/营业总收入 (%)-8.008-9.1484.1615.0766.976
净利润/营业总收入 (%)-10.197-11.2353.2074.4687.462

收益指标分析
经营活动净收益/利润总额(%)42.15299.575142.742105.69099.087
价值变动净收益/利润总额(%)-1.652-4.0081.829-0.4511.138
营业外收支净额/利润总额(%)2.6341.100-4.401-3.800-2.407

偿债能力分析
流动比率 (X)1.9791.5442.0981.6032.054
速动比率 (X)1.6521.2661.5951.2621.665
资产负债率 (%)36.82636.33737.52439.13933.474
带息债务/全部投入资本 (%)17.66715.51018.28613.63010.935
股东权益/带息债务 (%)447.178523.520431.127612.764792.225
股东权益/负债合计 (%)172.649175.468166.158155.074198.333
利息保障倍数 (X)-13.146-16.83331.635-20.734-9.695

营运能力分析
应收账款周转天数 (天)74.36480.84171.67291.00781.032
存货周转天数 (天)150.616180.606167.538168.463153.642